Mode of Action of Aspirin in Experimental Autoimmune Encephalomyelitis

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a central nervous system autoimmune disorder characterized by myelin destruction.
• Experimental autoimmune encephalomyelitis (EAE) serves as a key animal model for studying MS pathogenesis and therapeutic strategies.
• A decrease in regulatory T cells (Tregs) and an increase in T-helper 1 (Th1) and T-helper 17 (Th17) cells are implicated in MS and EAE.

Purpose of the Study:

• To investigate the therapeutic potential of low-dose aspirin in an animal model of multiple sclerosis (MS).
• To elucidate the underlying mechanisms by which aspirin exerts its protective effects in experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• Administration of low-dose aspirin to mice with EAE.
• Assessment of Treg, Th1, and Th17 cell populations.
• Measurement of interleukin-11 (IL-11) levels.
• Analysis of cAMP-response element-binding (CREB) activation and its role in IL-11 gene transcription.

Main Results:

• Low-dose aspirin significantly suppressed the disease progression in EAE mice.
• Aspirin treatment led to an upregulation of Tregs and a downregulation of Th1 and Th17 cells.
• Aspirin was found to increase IL-11 levels, which were sufficient to protect Tregs.
• The protective effect of aspirin was dependent on Tregs and mediated by CREB-stimulated IL-11 production.

Conclusions:

• Low-dose aspirin demonstrates therapeutic efficacy in EAE, likely through the modulation of T cell responses.
• The aspirin-mediated protection in EAE is critically dependent on the induction of Tregs.
• Aspirin promotes Treg stability and function via the CREB-mediated induction of IL-11, suggesting a novel therapeutic pathway for MS.